Neurocrine Biosciences - Ingrezza 2026 Net Sales Guidance Raised To $2.9 Billion-$2.93 Billion - SEC Filing

What happened

Neurocrine Biosciences said in an SEC filing that it raised its 2026 net sales guidance for Ingrezza to $2.9 billion-$2.93 billion. It reported third-quarter 2026 revenue of $1.10 billion, up 41% from a year earlier, and Ingrezza net product sales of $801 million, up 17%.

Confirmed

Global impact / market context

Ingrezza is the company's main revenue driver, so the higher 2026 sales guidance signals management expects stronger demand ahead. That matters because more product sales can raise revenue and cash available for research, debt payments, or shareholder returns, while also shaping investor expectations for future profit.

Analyst inference

The filing points to fast growth: total quarterly revenue rose 41% and Ingrezza sales rose 17%. Because the raised guidance covers a future year, it tells investors management sees continued expansion, not just a one-quarter gain. For a drug-focused company, such guidance often shapes how investors judge future revenue and profit per sale.

Analyst inference

What to watch

1. Watch whether Neurocrine actually delivers the raised 2026 Ingrezza net sales guidance of $2.9 billion-$2.93 billion; missing that target could change expectations for revenue and cash available. Confirmed
2. Watch whether the company sustains Ingrezza sales growth of 17% and total revenue growth of 41% in later quarters, since slower growth would weaken the case for the raised guidance. Proposed
3. Watch research and operating spending, because higher costs would reduce how much of the rising Ingrezza revenue turns into profit per sale and cash available for investors. Analyst inference

Evidence

• Original source link unavailable